Nothing Special   »   [go: up one dir, main page]

BR112017003881A2 - derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak - Google Patents

derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak

Info

Publication number
BR112017003881A2
BR112017003881A2 BR112017003881A BR112017003881A BR112017003881A2 BR 112017003881 A2 BR112017003881 A2 BR 112017003881A2 BR 112017003881 A BR112017003881 A BR 112017003881A BR 112017003881 A BR112017003881 A BR 112017003881A BR 112017003881 A2 BR112017003881 A2 BR 112017003881A2
Authority
BR
Brazil
Prior art keywords
aryl
ftl3
amino
jak inhibitors
macrocyclic polyether
Prior art date
Application number
BR112017003881A
Other languages
English (en)
Inventor
Gomes Bruno
Bachir Kaloun El
Schmitt Philippe
Grisoni Serge
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112017003881A2 publication Critical patent/BR112017003881A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

a presente invenção refere-se a um composto de fórmula (i) a seguir: fórmula (i), ou um sal e/ou um solvato farmaceuticamente aceitável deste, notadamente para sua utilização como medicamento, notadamente no tratamento do câncer, assim como as composições farmacêuticas que as contém e os respectivos processos de preparo.
BR112017003881A 2014-09-02 2015-09-02 derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak BR112017003881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1458203A FR3025199B1 (fr) 2014-09-02 2014-09-02 Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
PCT/EP2015/070066 WO2016034634A1 (fr) 2014-09-02 2015-09-02 Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak

Publications (1)

Publication Number Publication Date
BR112017003881A2 true BR112017003881A2 (pt) 2017-12-26

Family

ID=51842564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003881A BR112017003881A2 (pt) 2014-09-02 2015-09-02 derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak

Country Status (14)

Country Link
US (1) US20170281622A1 (pt)
EP (1) EP3189060B1 (pt)
JP (1) JP2017532299A (pt)
CN (1) CN106795173B (pt)
BR (1) BR112017003881A2 (pt)
DK (1) DK3189060T3 (pt)
ES (1) ES2686828T3 (pt)
FR (1) FR3025199B1 (pt)
HU (1) HUE040648T2 (pt)
MX (1) MX2017002627A (pt)
PL (1) PL3189060T3 (pt)
RU (1) RU2017108932A (pt)
TR (1) TR201813294T4 (pt)
WO (1) WO2016034634A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080090390A (ko) * 2005-11-16 2008-10-08 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents

Also Published As

Publication number Publication date
CN106795173B (zh) 2019-05-31
MX2017002627A (es) 2017-09-19
JP2017532299A (ja) 2017-11-02
RU2017108932A (ru) 2018-10-03
WO2016034634A1 (fr) 2016-03-10
ES2686828T3 (es) 2018-10-22
DK3189060T3 (en) 2018-10-01
EP3189060A1 (fr) 2017-07-12
EP3189060B1 (fr) 2018-06-20
RU2017108932A3 (pt) 2019-01-23
HUE040648T2 (hu) 2019-03-28
CN106795173A (zh) 2017-05-31
TR201813294T4 (tr) 2018-11-21
PL3189060T3 (pl) 2019-03-29
FR3025199A1 (fr) 2016-03-04
FR3025199B1 (fr) 2016-09-23
US20170281622A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
EA201692003A1 (ru) Макроциклические производные пиримидина
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112017026191A2 (pt) compostos tricíclicos e seu uso como inibidores de fosfodiesterase
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
TR201819805T4 (tr) Flavaglin türevleri̇.
BR112017003651A2 (pt) derivados de isoquinolinona úteis no tratamento de câncer
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.